141 related articles for article (PubMed ID: 12793098)
1. [Myocardial infarction in the course of antiretroviral therapy with protease inhibitor].
Buccoliero G; Lonero G; Rollo MA; Cristiano L; Romanelli C; Loperfido P; Chimienti A; Angelini P; Resta F
Recenti Prog Med; 2003 Jun; 94(6):264-6. PubMed ID: 12793098
[TBL] [Abstract][Full Text] [Related]
2. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
3. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
[TBL] [Abstract][Full Text] [Related]
6. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
8. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.
Cohen CJ
AIDS Read; 2005 Oct; 15(10):528-32, 537-8. PubMed ID: 16265768
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
10. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
11. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4).
Guiguet M; Mary-Krause M; Ename B; Costagliola D; Grabar S
Pharmacoepidemiol Drug Saf; 2008 May; 17(5):468-74. PubMed ID: 18324608
[TBL] [Abstract][Full Text] [Related]
12. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM
Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403
[TBL] [Abstract][Full Text] [Related]
13. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
[TBL] [Abstract][Full Text] [Related]
14. HIV protease inhibitors and dyslipidemia.
Clotet B; Negredo E
AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral drugs and the risk of myocardial infarction.
Zangerle R; Sarcletti M
N Engl J Med; 2007 Aug; 357(7):715-6; author reply 716-7. PubMed ID: 17703532
[No Abstract] [Full Text] [Related]
16. [Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():42-3. PubMed ID: 19024917
[No Abstract] [Full Text] [Related]
17. Trends in rates of myocardial infarction among patients with HIV.
Holmberg SD; Moorman AC; Greenberg AE
N Engl J Med; 2004 Feb; 350(7):730-2; author reply 730-2. PubMed ID: 14960752
[No Abstract] [Full Text] [Related]
18. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
Bucher HC; Young J; Battegay M
J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
[TBL] [Abstract][Full Text] [Related]
20. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
Hiransuthikul N; Hiransuthikul P; Kanasook Y
Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]